Presentation of Wouter De Maeseneire

SOME PHARMA FINANCIALS

PROF. DR. WOUTER DE MAESENEIRE

DISCLAIMER

I am not a pharma/healthcare expert

But I did quite some work for student in-company projects or customized trainings for

Pfizer, J&J (Janssen), Arseus, Capsugel, UCB, Boehringher-Inghelheim,…

IRC MFM last year: UCB

I wrote a case on BigPharma vs Small BiotechFSA

I’ll give a broad overview of some of the issues

© Vlerick Business School3

© Vlerick Business School

PROFIT AND LOSS ACCOUNT/INCOME STATEMENT

4

© Vlerick Business School

APPLE: PROFIT AND LOSS ACCOUNT (P&L)

5

© Vlerick Business School

DO YOU KNOW…

6

© Vlerick Business School

AN UNFORESEEN OUTCOME…

7

© Vlerick Business School

LIPITOR

Peak sales

Cumulative sales (1996-2012)

8

© Vlerick Business School

PFIZER: PROFIT AND LOSS ACCOUNT (P&L)

9

12

13

14

15

16

17

18

© Vlerick Business School

GALAPAGOS

19

© Vlerick Business School

GALAPAGOS: P&L

20

© Vlerick Business School21

© Vlerick Business School

GALAPAGOS: ASSETS

22

© Vlerick Business School

GALAPAGOS: EQUITY AND LIABILITIES

23

© Vlerick Business School

GALAPAGOS: CASH FLOW STATEMENT

24

© Vlerick Business School

A LOT OF BIG PHARMA & SMALL BIOTECHDEALS

M&A, alliances, milestone payments, co-development, licencsing out,…

Clear complementarities

25